Shareprice
18 Apr 2024

Precision Surgery Improving Outcomes for Cancer Patients

FluoGuide is a clinical-stage biotech company, elevating precision surgery with FG001, illuminating cancer cells during surgery to enhance outcomes for patients

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

LatestPress & news

20 Mar 2024 Minutes from Annual General Meeting in FluoGuide A/S News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR
13 Mar 2024 Chief Financial Officer (CFO) Ole Larsen buys shares News Corporate Action Other English Regulatory Listing Regulation IR

FluoGuideAn introduction

FluoGuide develops drugs for maximizing surgical outcomes by making cancer fluorescent.

Successful application of FluoGuide’s products will lower system-wide healthcare costs because it will reduce the recurrence of cancer and lessen general surgical complications. Thereby, patients will require fewer readmissions to hospitals.

Project StatusRapidly progressing pipeline

FluoGuide’s pipeline consists of product candidates that can potentially make most solid cancers fluorescent. We advance our pipeline at a rapid pace for the benefit of patients with cancer, society, and our shareholders. FluoGuide’s lead-product, FG001, is in phase IIa clinical development targeting patients undergoing surgical removal of high-grade glioma. FluoGuide is also developing FG001 in lung cancer and Head & Neck cancer.

Pipeline

Pre-clinical
Phase I
Phase II
Phase III
Commercial
FG001
Aggressive brain cancer (FGS)
Info
Next milestone: Consolidated plans
Head & Neck cancer (FGS)
Info
Next milestone: Consolidated plans
Lung cancer (FGS)
Info
Next milestone: Consolidated plans
Aggressive brain cancer (PTT)
Info
Next milestone: Consolidated plans
Follow-on pipeline
FG002
Info
Next milestone: CTA submission
Progress

FluoGuideCalendar & events

Latest presentations

28 February 2024

Annual report interview with Redeye

28 February 2024

FluoGuide introduction with HC Andersen Capital

Subscribe for newsletter